Home›Search›CANCER DRUG RESISTANCE

CANCER DRUG RESISTANCE

OAE PUBLISHING INC · US · Est. 2006

ISSN2578-532XeISSN2578-532X

SJR Q1✓ WOS ESCI✓ Scopus / SJR

/ 100

High Trust

PubScope credibility score from verifiable indexing & ethics signals

Score Breakdown

◆ Scopus Q178

✓ Corroboration (2 more)+12

Total90

Third-party records · how this is calculated · Report an error →

⚡ Speed vs Prestige

How does this journal balance review speed with impact level?

Publication speed: not measurable

publisher doesn’t disclose per-article submission dates — we never estimate

SJR Rank

Top 25% in field

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (ESCI) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1 · Scopus CiteScore 8.3. Source: Clarivate Journal Citation Reports.

SJR Scorei

1.775

H-Indexi

CiteScorei

8.3

SNIPi

0.918

Total Worksi

504

Total Citationsi

8,701

2yr Mean Citednessi

4.93

Open Impact Factor alternative

Aims & Scope

Cancer Drug Resistance aims to publish high-quality original research articles, reviews, and commentaries on all aspects of cancer drug resistance. The journal covers topics such as mechanisms of resistance, biomarkers of resistance, novel therapeutic strategies to overcome resistance, and the role of the tumor microenvironment in drug resistance. We welcome submissions on preclinical and clinical studies, as well as translational research that bridges basic science and clinical application.

General Information

Country / RegionUS

Primary LanguageEnglish

1st Year Published2006

Annual Volume~ 56 articles / year

StatusActive (last: 2026)

Total Publications504

OA Since2017

Visit Journal Website

Submission Info

Peer Reviewsingle-blind

Review Time—

Acceptance Rate—

OA License—

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✓ Yes

Think.Check.Submit Compliance

thinkchecksubmit.org

8/12 · 67%

✅

Do you know the journal / publisher?

OAE PUBLISHING INC

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

2578-532X / 2578-532X

✅

Indexed in a trusted database?

WoS, Scopus, PubMed

✅

Peer review process documented?

single-blind

❌

Follows ethical publishing standards (COPE)?

N/A

❌

APC fees clearly disclosed?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

✅

Plagiarism detection in place?

Yes

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

2.7k

2019

1.7k

2020

1.1k

2021

1.4k

2022

895

2023

468

2024

299

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Cancer ResearchQ1

Pharmacology (medical)Q1

Subject Classification

Web of Science Categories

Oncology

Research Topics (OpenAlex)

Cancer Immunotherapy and BiomarkersCancer Cells and MetastasisCancer Genomics and DiagnosticsMicroRNA in disease regulationEpigenetics and DNA MethylationCancer, Hypoxia, and MetabolismCancer therapeutics and mechanismsHistone Deacetylase Inhibitors ResearchCancer-related molecular mechanisms researchHER2/EGFR in Cancer Research

Frequently asked questions about CANCER DRUG RESISTANCE

Is CANCER DRUG RESISTANCE a predatory journal?

PubScope has no integrity flags on record for CANCER DRUG RESISTANCE: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 90/100. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of CANCER DRUG RESISTANCE?

CANCER DRUG RESISTANCE is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. As an open alternative, its Scopus CiteScore is 8.3.

Is CANCER DRUG RESISTANCE indexed in Scopus and Web of Science?

CANCER DRUG RESISTANCE is indexed in Web of Science, Scopus.